Can Tyvaso change the treatment pathway for idiopathic pulmonary fibrosis after TETON-1?
IPF has few durable treatment options. Tyvaso’s TETON data may test whether inhaled therapy can reset the regulatory and commercial playbook.
Pharma & Biotech
Pharma & Biotech
Can IBI3002 help Innovent Biologics challenge the next wave of type 2 inflammation therapies?
Bispecific antibodies are moving beyond oncology. Innovent’s autoimmune pipeline now faces the harder test of clinical durability.
Pharma & Biotech
Can AeroRx turn nebulized COPD treatment into a first-line dual bronchodilator category?
COPD care relies on handheld inhalers, but many patients struggle with delivery. AeroRx is testing whether nebulized dual therapy can close that gap.